Method of reducing the harmful effects of orally or transdermally delivered nicotine

Abstract

The present invention generally relates to the reduction of the harmful effects of orally or transdermally delivered nicotine in conventional tobacco-use cessation programs. More specifically, embodiments concern methods of reducing the harmful effects of nicotine intake, associated with conventional tobacco-use cessation programs, by providing tobacco products, which contain a reduced amount of nicotine and/or tobacco specific nitrosamines (TSNAs).

1 . A tobacco use cessation kit comprising: 
 a first tobacco product that comprises nicotine and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g;    a second tobacco product that comprises an amount of nicotine that is less than the first tobacco product and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g, wherein said first tobacco product and said second tobacco product are cigarettes; and    a third tobacco product that comprises an amount of nicotine that is less than the amount of nicotine in said second tobacco product and delivers a collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μg/g, wherein said first tobacco product, said second tobacco product, and said third tobacco product are cigarettes and wherein said first tobacco product delivers less than 0.7 mg/g nicotine, said second tobacco product delivers less than 0.4 mg/g nicotine, and said third tobacco product delivers less than 0.5 mg/g nicotine.